Robert S Epstein sold $575k of VCYT
director at VERACYTE, INC.. 15,000 shares at an average of $38.32, traded Nov 12, 2024, filed Nov 14, 2024.
Score components
- +15RoleDirector
- +19Trade size$575k at market
- +10Share of holdings soldSold 25% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +16.7%, 3m +6.9%, 6m -23.1%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001384101-24-000165, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 12, 2024 | MOption exercise Common Stock10b5-1 | +15,000 | $8.04 | $121k | 59,598 | Nov 14, 2024 |
| Nov 12, 2024 | SOpen-market sale Common Stock10b5-1 | -15,000 | $38.32 | $575k | 44,598 | Nov 14, 2024 |
| Nov 12, 2024 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -15,000 | $0.00 | $0 | 20,000 | Nov 14, 2024 |
Related signals
Other insiders at VERACYTE, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 14Weak | VERACYTE, INC. | John Leite Global Chief Commercial Off | $161k 4,015 shares | -3% | |
| 27Weak | VERACYTE, INC. | Jens Holstein director | $205k 5,000 shares | -15% | |
| 28Weak | VERACYTE, INC. | Rebecca Chambers Chief Financial Officer | $157k 3,652 shares | -2% | |
| 29Weak | VERACYTE, INC. | Phillip G. Febbo Chief Scientific & Med Officer | $564k 13,110 shares | -9% | |
| 21Weak | VERACYTE, INC. | Annie McGuire EVP, General Counsel | $140k 3,254 shares | -2% | |
| 19Weak | VERACYTE, INC. | Muna Bhanji director | $80k 1,864 shares | -4% | |
| 35Weak | VERACYTE, INC. | Rebecca Chambers Chief Financial Officer | $663k 18,341 shares | -12% | |
| 26Weak | VERACYTE, INC. | Phillip G. Febbo Chief Scientific & Med Officer | $485k 13,425 shares | -10% | |
| 32Weak | VERACYTE, INC. | Annie McGuire SVP, General Counsel | $463k 10,739 shares | -14% | |
| 39Weak | VERACYTE, INC. | Karin Eastham director | $909k 20,000 shares | -60% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.